Boston Scientific Corporation Dossier

Boston Scientific Corporation, a prominent entity in the global medical technology sector, presented its financial results for the fiscal 2025 period ending September 30. The company reported revenues reaching $5.065 billion and generated an operating income of $1.418 billion. Performance during the period was primarily driven by its Cardiovascular segment, which accounted for $3.123 billion in sales. The company's MedSurg segment also provided a significant contribution, posting revenues of $1.942 billion, showcasing a balanced and diversified operational structure.

Financial Highlights

* Revenue: $5.065 billion

* Gross Margin: 71.8%

* Operating Income: $1.418 billion

* Net Income: $755 million

* Diluted EPS: $0.51

* Free Cash Flow: $1.16 billion

* R&D Spending: $550 million

* Book Value Per Share: $18.78

The financial data for fiscal 2025 provides a clear picture of Boston Scientific Corporation’s strategic priorities and operational execution. The results highlight a business model anchored in its two core segments, with the Cardiovascular division... Sign in / Sign up to learn more about Boston Scientific Corporation

Continue your research by chatting with our AI financial analyst about Boston Scientific Corporation. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given that Boston Scientific Corporation's Cardiovascular segment grew 22.8% in Q3 FY2025, significantly outpacing the 16.4% growth in its MedSurg segment, what specific products and market share gains are driving this outperformance, and how sustainable is this growth trajectory?
• Boston Scientific Corporation reported expanding operating margins and a free cash flow conversion rate of 153.6% in its latest FY2025 quarterly results. What are the key operational efficiencies or product mix shifts driving this strong profitability and cash generation?
• With a stated strategy of pursuing 'tuck-in' M&A, Boston Scientific Corporation recently acquired SoniVie and Bolt Medical. How do these acquisitions fit within the company's existing segments, and what are the potential impacts on its revenue growth and R&D pipeline for the remainder of FY2025?
• Boston Scientific Corporation raised its full-year FY2025 revenue growth guidance to a range of 14.5% to 15.5%. Considering the near-term catalysts like the Farapulse PFA system, what is the breakdown of expected contributions from organic growth versus recently acquired businesses to achieve this target?
• Considering Boston Scientific Corporation's debt-to-equity ratio of 0.45 and significant capital deployment on acquisitions, how does the company's current capital structure support its aggressive growth strategy, and what financial leverage risks should investors monitor?